Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.

about

Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.

Item

http://www.wikidata.org/entity/Q52330065

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Pharmacokinetics of efavirenz ...... ountries: a systematic review.

@en

Pharmacokinetics of efavirenz ...... ountries: a systematic review.

@nl

type

Item

label

Pharmacokinetics of efavirenz ...... ountries: a systematic review.

@en

Pharmacokinetics of efavirenz ...... ountries: a systematic review.

@nl

prefLabel

Pharmacokinetics of efavirenz ...... ountries: a systematic review.

@en

Pharmacokinetics of efavirenz ...... ountries: a systematic review.

@nl

P1476

Pharmacokinetics of efavirenz ...... ountries: a systematic review.

@en

P2093

Anne-Marie Taburet

http://www.w3.org/2001/XMLSchema#string

Maryline Bonnet

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all

Pharmacogenomics knowledge for personalized medicine

Structural mechanism for rifampicin inhibition of bacterial rna polymerase

Role of individual drugs in the chemotherapy of tuberculosis

Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients

Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

P304

1641-1658

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13600

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniel Atwine

P577

2018-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29624706

http://www.w3.org/2001/XMLSchema#string

P932

6046471

http://www.w3.org/2001/XMLSchema#string